Capital Investment Advisory Services’s AbbVie ABBV Stock Holding History

Capital Investment Advisory Services’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.83M	Sell	35,075 -11,302	-24%	-$2.43M	0.54%	38
2026 Q1	$10.1M	Sell	46,377 -1,662	-3%	-$369K	0.74%	26
2025 Q4	$11M	Buy	48,039 +547	+1%	+$125K	0.78%	23
2025 Q3	$11M	Sell	47,492 -1,359	-3%	-$277K	0.87%	18
2025 Q2	$9.07M	Sell	48,851 -777	-2%	-$144K	0.74%	28
2025 Q1	$10.4M	Buy	49,628 +11,576	+30%	+$2.25M	0.93%	18
2024 Q4	$6.76M	Sell	38,052 -516	-1%	-$94.9K	0.65%	32
2024 Q3	$7.62M	Sell	38,568 -1,587	-4%	-$296K	0.72%	27
2024 Q2	$6.89M	Buy	40,155 +108	+0.3%	+$17.9K	0.71%	30
2024 Q1	$7.29M	Sell	40,047 -2,144	-5%	-$370K	0.78%	21
2023 Q4	$6.54M	Buy	42,191 +1,053	+3%	+$154K	0.6%	30
2023 Q3	$6.13M	Sell	41,138 -452	-1%	-$66.4K	0.6%	25
2023 Q2	$5.6M	Buy	41,590 +482	+1%	+$70.7K	0.55%	28
2023 Q1	$6.55M	Sell	41,108 -1,730	-4%	-$264K	0.77%	23
2022 Q4	$6.92M	Buy	42,838 +9,382	+28%	+$1.44M	0.82%	19
2022 Q3	$4.49M	Sell	33,456 -461	-1%	-$66.2K	0.58%	33
2022 Q2	$5.2M	Buy	33,917 +2,774	+9%	+$424K	0.63%	28
2022 Q1	$5.05M	Buy	31,143 +486	+2%	+$70.6K	0.55%	29
2021 Q4	$4.15M	Buy	30,657 +1,271	+4%	+$150K	0.49%	44
2021 Q3	$3.17M	Buy	29,386 +2,530	+9%	+$289K	0.4%	51
2021 Q2	$3.02M	Sell	26,856 -281	-1%	-$31.6K	0.38%	58
2021 Q1	$2.94M	Buy	27,137 +164	+0.6%	+$17.5K	0.41%	54
2020 Q4	$2.89M	Buy	26,973 +1,826	+7%	+$175K	0.43%	52
2020 Q3	$2.2M	Sell	25,147 -2,860	-10%	-$269K	0.41%	58
2020 Q2	$2.75M	Buy	28,007 +167	+0.6%	+$14.7K	0.56%	40
2020 Q1	$2.12M	Sell	27,840 -3,099	-10%	-$264K	0.52%	40
2019 Q4	$2.74M	Buy	30,939 +3,262	+12%	+$271K	0.73%	26
2019 Q3	$2.1M	Buy	27,677 +12,337	+80%	+$846K	0.58%	33
2019 Q2	$1.04M	Buy	15,340 +6,759	+79%	+$531K	0.32%	65
2019 Q1	$692K	Buy	8,581 +193	+2%	+$15.8K	0.26%	77
2018 Q4	$773K	Sell	8,388 -740	-8%	-$65.1K	0.33%	58
2018 Q3	$863K	Buy	9,128 +20	+0.2%	+$1.9K	0.4%	59
2018 Q2	$844K	Buy	9,108 +3,693	+68%	+$361K	0.42%	58
2018 Q1	$513K	Buy	5,415 +1,035	+24%	+$114K	0.29%	85
2017 Q4	$424K	Buy	4,380 +705	+19%	+$66.4K	0.25%	103
2017 Q3	$327K	Sell	3,675 -8,340	-69%	-$635K	0.2%	124
2017 Q2	$871K	Sell	12,015 -706	-6%	-$47.5K	0.57%	43
2017 Q1	$829K	Sell	12,721 -35	-0.3%	-$2.2K	0.61%	41
2016 Q4	$799K	Buy	+12,756	New	+$779K	0.69%	40

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capital Investment Advisory Services's ABBV Position: Q2 2026 in Review

Capital Investment Advisory Services reduced its AbbVie (ABBV) stake by 24% in Q2 2026, selling an estimated $2.43M and leaving 35,075 shares worth $8.83M. The position accounts for 0.54% of the portfolio, ranked #38.

Capital Investment Advisory Services first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. The position peaked at $11M in Q3 2025. 3,650 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Capital Investment Advisory Services held 35,075 shares of AbbVie worth $8.83M as of Q2 2026.
Capital Investment Advisory Services sold 11,302 AbbVie shares in Q2 2026, an estimated $2.43M.
AbbVie made up 0.54% of Capital Investment Advisory Services's portfolio in Q2 2026, its #38 holding.
Capital Investment Advisory Services first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
Capital Investment Advisory Services's AbbVie position peaked at $11M in Q3 2025.
3,650 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capital Investment Advisory Services's 13F filing for Q2 2026, filed 23 Jul 2026.